Pull to refresh
Logo
Pfizer's oral drug restores skin pigment in vitiligo trials

Pfizer's oral drug restores skin pigment in vitiligo trials

New Capabilities

An oral JAK inhibitor moved from mid-stage promise to a successful Phase 3, aiming to become the first pill for the pigment-loss disease.

6 days ago: Phase 3 trials succeed

Overview

For most of medical history, vitiligo had no fix. Doctors could sometimes slow the spreading white patches, but regrowing lost skin color was mostly out of reach.

Pfizer is testing a daily pill to change that. Its drug, ritlecitinib, calms the immune attack on pigment cells and lets color return to skin. In July 2026, two large Phase 3 trials showed it worked.

Why it matters

Roughly 1 in 100 people have vitiligo. A pill that regrows lost skin color could become the first systemic treatment for the disease.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

28.5M
People diagnosed worldwide
Estimated global lifetime prevalence of physician-diagnosed vitiligo.
2,174
Phase 3 patients
Combined enrollment in the TRANQUILLO and TRANQUILLO 2 trials across 271 sites.
26.7%
Facial repigmentation response (Phase 2b, week 48)
Share of patients reaching 75% facial repigmentation after 48 weeks in the mid-stage study.
1
Approved repigmentation drugs (all topical)
Only Incyte's ruxolitinib cream is FDA-approved to restore pigment; no pill exists yet.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 3 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Organizations Involved

Timeline

July 2022 July 2026

5 events Latest: 6 days ago
Tap a bar to jump to that date
  1. Phase 3 trials succeed

    Latest Clinical Data

    Pfizer said both TRANQUILLO Phase 3 trials met their co-primary goals at 52 weeks across 2,174 patients. The company plans to seek approval globally.

  2. Extension study adds phototherapy

    Clinical Data

    Phase 2b extension results in the Journal of the American Academy of Dermatology showed pairing the pill with narrow-band UVB light improved repigmentation, with response rising over 48 weeks.

  3. Reports say Pfizer's pill regrows skin color

    Clinical Data

    News outlets reported that oral ritlecitinib restored pigment in vitiligo patients during Pfizer's trial. The mid-stage results built the case to advance to Phase 3.

  4. Ritlecitinib approved for a hair-loss disease

    Regulatory

    The FDA approved ritlecitinib as LITFULO for severe alopecia areata. The approval set the pill's safety profile and cleared the way to test it in vitiligo.

  5. FDA approves first repigmentation drug

    Regulatory

    The FDA approved Opzelura, a ruxolitinib cream from Incyte. It was the first treatment proven to restore skin color in nonsegmental vitiligo, but practical only for limited areas.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

July 2022

Opzelura wins first vitiligo approval (2022)

The FDA approved Incyte's ruxolitinib cream after the TRuE-V trials, which enrolled about 600 patients. It was the first drug ever proven to restore pigment in vitiligo, not just cover or slow it.

Then

Patients gained their first proven repigmentation option, though the cream suits limited areas like the face.

Now

The approval set the trial endpoints, the facial and total-body scoring indexes, that Pfizer's oral drug now has to beat.

Why this matters now

It is the benchmark Pfizer must clear. A pill would extend treatment to people whose disease is too widespread for a cream.

September 2021

FDA orders boxed warnings on JAK pills (2021)

After a safety study of tofacitinib called ORAL Surveillance, the FDA required boxed warnings across oral JAK inhibitors. The warnings flag serious infections, blood clots, cancer, and heart events.

Then

The warnings narrowed how broadly doctors could prescribe oral JAK drugs.

Now

Every new oral JAK inhibitor, including ritlecitinib, carries the class warning.

Why this matters now

It shapes how freely a vitiligo pill can be used. Regulators weigh serious risks against a disease that is not life-threatening.

2003-2010

Biologics remake psoriasis treatment (2000s)

Systemic immune drugs like etanercept and adalimumab moved psoriasis care beyond creams and light boxes. They cleared skin for many patients and built a multibillion-dollar market.

Then

Patients with severe disease gained durable clearance for the first time.

Now

Systemic therapy became the standard for widespread skin disease, reshaping treatment and drug economics.

Why this matters now

It shows the path Pfizer hopes to repeat: a systemic option can reset how a common skin disease is treated and paid for.

Sources

(6)